Cidara Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
RA Capital Management, L.P. and its affiliates reported the disposition of all their holdings in Cidara Therapeutics, Inc. following its acquisition by Merck.
Cidara Therapeutics director Joshua Resnick's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.
Cidara Therapeutics, Inc. completed its merger with a Merck subsidiary, converting all outstanding stock options into cash at $221.50 per common share.
Director James Merson's stock options in Cidara Therapeutics were converted to cash following the company's acquisition by Merck on January 7, 2026.
Cidara Therapeutics director Carin Canale-Theakston's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.
Cidara Therapeutics director Bonnie L. Bassler reports disposition of shares and options following the company's acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.
Cidara Therapeutics, Inc. director Chrysa Mineo reports disposition of shares and options following its acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.
Director Theodore R. Schroeder's stock options in Cidara Therapeutics were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.
Cidara Therapeutics, Inc. completed its merger with Merck, with shareholders receiving $221.50 per common share and $15,505.00 per Series A preferred share in cash.
Jeffrey Stein, President & CEO of Cidara Therapeutics, Inc., disposed of all his common stock and derivative securities following the company's acquisition by Merck Sharp & Dohme LLC.
Cidara Therapeutics' CFO, Frank Karbe, disposed of all his common stock, restricted stock units, and stock options as part of the company's acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.
Cidara Therapeutics, Inc. has been acquired by Merck Sharp & Dohme LLC, with common shares tendered at $221.50 each.
Cidara Therapeutics Chief Medical Officer Nicole Negar Davarpanah reported the disposition of common stock, restricted stock units, and employee stock options following the company's acquisition by Merck.
Cidara Therapeutics' President & CEO, Jeffrey Stein, filed an amended Form 4 to correct historical beneficial ownership reports, reflecting a 1-for-20 reverse stock split and clarifying transaction details.
Cidara Therapeutics' Chief Medical Officer, Nicole Negar Davarpanah, gifted 450 shares of common stock to a donor-advised fund for charitable purposes.
Cidara Therapeutics President & CEO Jeffrey Stein reported multiple gift transfers of common stock to a trust and a donor-advised fund, alongside an Employee Stock Purchase Plan acquisition.
Cidara Therapeutics' President and CEO, Jeffrey Stein, reported the withholding of shares for taxes and acquisition of shares through an employee stock purchase plan.
Cidara Therapeutics' CFO, Frank Karbe, reported the disposition of 7,290 common shares for tax withholding on December 10, 2025, alongside an ESPP acquisition.
Cidara Therapeutics' COO & CLO, Shane Ward, reported exercising stock options and subsequently selling a portion of his common stock holdings.
Cidara Therapeutics' Chief Medical Officer, Nicole Davarpanah, reported the disposition of 10,332 common shares to cover tax obligations from RSU vesting, while also acquiring 200 shares via ESPP.
Cidara Therapeutics' Chief Medical Officer, Nicole Negar Davarpanah, sold 474 shares of common stock to cover tax withholding obligations related to RSU vesting.
RA Capital Management, a major institutional investor and director, acquired over 2.2 million shares of Cidara Therapeutics common stock for $44 per share, boosting its beneficial ownership to over 3.3 million shares.
A Form 4 filing reveals that Joshua Resnick, a director of Cidara Therapeutics affiliated with RA Capital Management, L.P., was granted 5,079 stock options with an exercise price of $21.31, vesting by June 2026.
Cidara Therapeutics, Inc. Director Joshua Resnick has reported the acquisition of 5,079 stock options with an exercise price of $21.31, granted on June 18, 2025, as part of his annual director compensation.
Cidara Therapeutics, Inc. Director Ryan Spencer was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026.
Cidara Therapeutics, Inc. director Theodore R. Schroeder was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026 or the 2026 annual meeting.
Cidara Therapeutics, Inc. Director Chrysa Mineo was granted 11,100 stock options with an exercise price of $21.31, vesting over approximately one year.
James Merson, a Director at Cidara Therapeutics, Inc. (CDTX), was granted 11,100 stock options with an exercise price of $21.31, aligning his interests with shareholder value.
Cidara Therapeutics, Inc. Director Carin Canale-Theakston was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026.
Cidara Therapeutics, Inc. Director Daniel D. Burgess has been granted 11,100 stock options with an exercise price of $21.31, as disclosed in a recent SEC Form 4 filing.